The second largest IT services company, Infosys, reported 0.7% rise consolidated net profit to Rs 7,823 crore in the September quarter from Rs 7,769 crore in the June quarter.

HDFC Securities has reviewed the Q2 FY27 performance of nine companies, including Infosys, Shriram Finance, SBI Cards, IndusInd Bank, DCB Bank, Torrent Pharma, Dr. Reddy's Labs, HPCL and Godrej Properties, retaining its existing ratings across all 9 stocks while revising target prices for eight.

JPMorgan lowered its target price on SBI Cards to Rs 505 from Rs 588, citing muted loan growth, potential net interest margin (NIM) pressure and the likelihood of credit costs bottoming out.

IDFC First Bank reported Q2 FY27 net profit of Rs 1,040 crore, led by healthy operating performance and robust business growth, says the brokerage.

Asian markets traded mixed, while the US stock market ended lower. Crude oil prices eased, while gold pries steadied ahead of the US Federal Reserve's interest rate decision this week.

Brent crude falls below $116 a barrel as investors weigh the risk of further conflict in the Middle East against a recovery in oil shipments

Brokerages largely retained a constructive view on the lender, citing healthy loan growth, improving asset quality and the potential for earnings growth. However, margin pressure and higher provisions remain key factors to monitor.

A data scientist terminated during probation seeks advice on rebuilding confidence, identifying startup red flags, and distinguishing skill gaps from poor workplace support, particularly in AI-first companies with limited onboarding, documentation and mentorship.

The impact of exiting the Daimler deal is expected to be largely felt in Q4, creating uncertainty around the exit growth rate in FY28, adds the brokerage.

Ranabaali is set in South India in the 1870s and follows a warrior who fights against colonial rule during a time of famine and also explores his relationship with his wife, Jayamma, while blending history, folklore, action and drama.

Stocks in the news, big brokerage calls of the day, complete trade setup and much more!

Dr. Reddy's Laboratories delivered a sharp margin recovery and beat profit expectations despite largely in-line revenue. Brokerages highlighted operating efficiencies and a stronger product mix, while identifying semaglutide supplies and abatacept approval as key catalysts for the coming quarters.